Exelixis Inc. (EXEL)
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is Why Growth Investors Should Buy Exelixis (EXEL) Now
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Earnings Estimates Rising for Exelixis (EXEL): Will It Gain?
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks?
Exelixis (EXEL) Reliance on International Sales: What Investors Need to Know
Explore how Exelixis' (EXEL) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine
Exelixis's Cabometyx continues to drive revenue growth, prompting a raised 2024 forecast to $2.15–$2.2 billion. EXEL plans to diversify its oncology portfolio by launching one new indication for Zanzalintinib annually. Zanzalintinib could also grow into a $5 billion yearly revenue asset by 2033, potentially surpassing Cabometyx as Exelixis's primary revenue source. The company has repurchased $462.4 million in shares this year, showcasing it's a shareholder-friendly company as well.
